TEANECK, N.J. and BLOOMFIELD, N.J., Oct. 27 /PRNewswire/ -- Eisai Inc. and U.S. Pharmacist announced today the winners of the Third Annual hhc (human health care) Pharmacy Recognition Award. The award acknowledges pharmacists who provide professional services to people affected by Alzheimer's disease by implementing programs to address issues such as early recognition, appropriate treatment and family caregiving.
Named for the company's hhc mission, the hhc Pharmacy Recognition Award emphasizes Eisai's commitment to satisfy unmet medical needs and to increase benefits to patients and their families worldwide. The award helps achieve this mission by recognizing pharmacists who have implemented initiatives that have enhanced the quality of care for Alzheimer's patients, either through patient screening and counseling or through improving the competencies of caregivers and healthcare providers through education.
"The pharmacists who are receiving this award truly aim to satisfy the unmet medical needs of patients and their families, and consistently go above and beyond the call of duty," said Lonnel Coats, president & COO of Eisai Inc., a Teaneck, NJ-based pharmaceutical company. Eisai discovered and developed Aricept(R) (donepezil hydrochloride tablets), the number-one prescribed medication worldwide for mild-to-moderate Alzheimer's disease. "Sponsoring this award with U.S. Pharmacist allows us to recognize those leaders who share our mission of human health care."
"Pharmacists are a consistent and credible source of information, but also serve the duty of counselor for patients and caregivers," said Angele C. D'Angelo, vice president & editor-in-chief of U.S. Pharmacist, a monthly journal that provides pharmacists with information relevant to the contemporary pharmacy practice. "This award raises awareness of their efforts and hopefully will inspire others in meeting both medical and educational needs of those affected by chronic illnesses."
The award recipients are licensed pharmacists practicing in one of four settings -- institutional, long-term care, managed care and community -- involved within the past 12 months in education or disease-state management of patients with Alzheimer's disease.
The four recipients are:
-- Angela J. Massey, PharmD, BCPP, received an award for her work in the
Institutional Care category. Dr. Massey was instrumental in developing
the Pharmacy Program at the Memory Disorder Clinic in Tallahassee, FL,
where she has provided nearly 600 medication evaluations for people
with memory decline. She has participated in screening programs about
managing medication-related issues and published articles on memory
disorder. Additionally, Dr. Massey is on the Board of Directors for
the Alzheimer's Resource Center of Florida where she leads monthly
support groups, educates and trains caregivers and publishes a
-- Manju T. Beier, PharmD, FASCP, was an award recipient in the Long-Term
Care category. Dr. Beier is a Senior Partner with Geriatric Consultant
Resources, a company specializing in the education and research needs
of pharmacists, physicians and other healthcare professionals
responsible for treating dementia. She has worked on the development
of continuing education programs specific to Alzheimer's and has given
more than 100 presentations on the disease at national and local
meetings of the Michigan Dementia Coalition.
-- Nadia A. Amruso, PharmD, CGP, received an award for her work in Managed
Care. Dr. Amruso implemented an Alzheimer's education program for
Eckerd pharmacists in the Tampa Bay, FL area. The program increases
awareness for the special needs of Alzheimer's patients and their
caregivers. Additionally, the program includes patient educational and
screening sessions, which facilitate early evaluation and diagnosis.
-- Stephen M. Setter, PharmD, CDE, CGP, DVM, was recognized with an award
for his work in the Community Pharmacy category. Dr. Setter leads a
group of pharmacists in Spokane, WA, who educate physicians and nurses
about the latest treatments for patients with Alzheimer's disease
including current diagnostic techniques and the latest research
initiatives. Dr. Setter also oversees a local student program that
provides an in-home review of medications for Alzheimer's patients.
His accomplishments as clinical pharmacist at Elder Services include
visiting more than 85 Alzheimer's patients and caregivers in their
homes to assist physicians in more proactively screening and treating
In addition to receiving a specially designed keepsake trophy and an honorarium, each of the winners will be profiled in a two-page article in U.S. Pharmacist (September through December 2004).
About Eisai Inc.
Eisai Inc. is a US pharmaceutical subsidiary of Eisai Co., Ltd., a research-based human health care company that discovers, develops, and markets products in more than 30 countries.
Established in 1995, Eisai Inc. began marketing its first product in the United States in 1997 and has rapidly grown to become an integrated pharmaceutical business with sales of more than $1.7 billion in fiscal year 2003 (year ending March 31, 2004).
Eisai Inc. employs approximately 1,100 people at its headquarters in Teaneck, NJ, at its state-of-the-art pharmaceutical production and formulation research and development facility in Research Triangle Park, NC, and in the field. Between 1998 and 2003, Eisai Inc. moved up rapidly in the rankings (based on revenues) of US pharmaceutical companies from No. 44 to No. 20.
About U.S. Pharmacist
U.S. Pharmacist is a monthly journal dedicated to providing the nation's pharmacists with up-to-date, authoritative, peer-reviewed clinical articles relevant to contemporary pharmacy practice in a variety of settings, including community pharmacy, hospitals, managed care systems, ambulatory care clinics, home care organizations, long-term care facilities, industry and academia. The publication is also useful to pharmacy technicians, students, other health professionals and individuals interested in health management.
Information About Aricept(R) (donepezil hydrochloride tablets) Treatment
While there is no cure for Alzheimer's disease, medical treatments are available to manage symptoms of the disease. Once-a-day prescription Aricept(R) is indicated for mild-to-moderate Alzheimer's disease.
In a progressively degenerative disease such as Alzheimer's, improvement, stabilization or a less-than-expected decline over time is considered a positive response to treatment. These types of responses have been observed in patients treated with Aricept(R) in clinical trials for Alzheimer's disease. Individual responses to treatment vary, and some patients may not respond.
Aricept(R) is well tolerated but may not be for everyone. People at risk for stomach ulcers or who take certain other medicines should tell their doctors because serious stomach problems, such as bleeding, may get worse. Some people may have nausea, diarrhea, not sleep well, or vomit. Some people may have muscle cramps, feel very tired, or may not want to eat. In studies, these were mild and went away over time. Some people who take Aricept may experience fainting.
Aricept(R) is the number-one prescribed Alzheimer's disease therapy worldwide, with more than 1 billion patient days of Aricept(R) therapy sold. More than 1.7 million people in the United States alone have begun Aricept(R) therapy.
Aricept(R) is co-promoted in the United States by Eisai Inc. and Pfizer Inc., which are dedicated to advances in Alzheimer's therapy.
For more information about managing Alzheimer's disease and about Aricept(R), please call (888) 999-9616, or visit http://www.aricept.com/. Full prescribing information is available at the web site.